Cerebrolysin

What it is

Cerebrolysin is a proprietary injectable preparation derived from porcine brain hydrolysate. Unlike single-sequence peptides such as semaglutide or Selank, Cerebrolysin is a complex mixture of low-molecular-weight peptides and free amino acids^{[4 –5 ]}. It has been marketed for neurologic indications in some countries outside the United States.

Composition — not a single sequence

Cerebrolysin is not a single defined peptide sequence. The manufacturer describes it as a solution for injection containing Cerebrolysin concentrate in aqueous solution, and peer-reviewed reviews describe it as a parenterally administered porcine brain-derived peptide preparation with low-molecular-weight peptides and amino acids^{[1 ,4 –5 ]}.

Mechanism — neurotrophic, not receptor-specific

The proposed mechanism is neurotrophic and neuroprotective rather than receptor-specific. Reviews describe pharmacodynamic properties similar to endogenous neurotrophic factors, with research interest in neuronal survival, plasticity, and recovery after neurologic injury^{[4 –7 ]}. Because the product is a mixture, mechanism claims are less straightforward than for a single active ingredient with a defined receptor target.

Cerebrolysin is often discussed in nootropic and recovery communities as a brain-repair peptide. That framing is broader than the evidence supports and can obscure major jurisdictional differences. The manufacturer states that Cerebrolysin is not registered with FDA and is not approved for sale or distribution in the United States^{[1 ]}.

When used clinically outside the United States, Cerebrolysin is an injectable prescription medication^{[1 ]}. This page does not provide dosing, importing, or administration guidance.

Regulatory status

Cerebrolysin is not FDA-approved for any indication in the United States. The manufacturer’s website includes a notice to US visitors stating that Cerebrolysin is not registered with FDA and is not approved for sale or distribution in the United States^{[1 ]}.

FDA import guidance applies

FDA’s general import guidance states that imported human drugs must meet FDA standards for quality, safety, and effectiveness and that FDA verifies requirements including drug applications, labeling, registration/listing, and cGMP compliance at import^{[2 ]}. FDA’s small-business import/export page states that importation of new drugs that lack FDA approval violates the Federal Food, Drug, and Cosmetic Act, whether for personal use or otherwise^{[3 ]}.

Not a typical compounding-pathway peptide

Cerebrolysin is not a typical pharmacy-compounding peptide. It is a proprietary animal-derived mixture rather than a single bulk drug substance. It was not identified on the FDA 503A or 503B bulks lists reviewed for this draft. A US clinician generally cannot prescribe an unapproved foreign drug as if it were an FDA-approved product; lawful clinical use would require an appropriate FDA-authorized investigational pathway.

The manufacturer describes the Austrian product as prescription-only and lists therapeutic indications in the Austrian Summary of Product Characteristics context, including cerebrovascular disorders, Alzheimer-type senile dementia, vascular dementia, stroke, and craniocerebral trauma^{[1 ]}. Those non-US indications do not create US approval.

Cerebrolysin was not identified in the federal controlled-substance schedules in 21 CFR Part 1308 as reviewed for this draft^{[8 ]}. Date of last regulatory verification: May 5, 2026.

Research summary

Acute ischemic stroke — Cochrane

Acute ischemic stroke has the largest systematic-review literature. The 2023 Cochrane review describes Cerebrolysin as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain and notes use in Russia, Eastern Europe, China, and other Asian and post-Soviet countries^{[5 ]}. Cochrane concluded that adding Cerebrolysin or a Cerebrolysin-like agent to standard therapy probably does not reduce mortality and that Cerebrolysin probably does not affect serious adverse events overall but increases serious non-fatal adverse events^{[5 ]}. This is a more cautious conclusion than many promotional summaries.

Post-stroke rehabilitation

Post-stroke rehabilitation studies have reported more positive findings in selected populations. Mitrovic and colleagues conducted a randomized, double-blind, placebo-controlled study of 60 patients in early severe subacute stroke rehabilitation, with Cerebrolysin or placebo plus rehabilitation^{[7 ]}. The abstract reports improved upper-limb motor recovery with extended rehabilitation combined with Cerebrolysin^{[7 ]}. This study is clinically relevant but small and should be weighed against broader systematic-review findings.

Vascular dementia

Vascular dementia has also been reviewed by Cochrane. The 2019 update included randomized controlled trials and concluded that evidence was uncertain or limited for important outcomes, with heterogeneity and risk-of-bias concerns^{[6 ]}. The review describes Cerebrolysin as a porcine brain-derived preparation said to have neurotrophic and neuroprotective activity^{[6 ]}.

Alzheimer disease and dementia

Alzheimer disease and mixed dementia evidence includes older randomized trials summarized in a 2009 review by Plosker and Gauthier^{[4 ]}. That review reported improvements in global and cognitive measures in several trials and described dizziness or vertigo as the most frequently reported adverse event^{[4 ]}. However, this review predates many current dementia-trial standards and should not be interpreted as FDA approval or modern US guideline endorsement.

Where the evidence ends

Traumatic brain injury and cognitive-impairment claims are common in international and online discussion, but evidence varies by indication, injury severity, timing, comparator, and rehabilitation context. This draft did not identify a US FDA-approved indication or a single decisive trial establishing Cerebrolysin as a standard US treatment for TBI, dementia, stroke, or cognitive enhancement.

Overall, Cerebrolysin has a larger clinical literature than most gray-market peptides, but it remains non-FDA-approved in the United States. The evidence should be presented as mixed by indication, with systematic reviews carrying more weight than promotional summaries or single positive trials.

Public discourse

The Cochrane Stroke review authors gave a cautious assessment of benefits and harms in acute ischemic stroke^{[5 ]}.

EVER Neuro Pharma, the manufacturer, explicitly states the US regulatory limitation on its public site^{[1 ]}.

Greg L. Plosker and Serge Gauthier, dementia review authors, summarized older dementia trials and described the product format^{[4 ]}.

The Cochrane Dementia review authors emphasized inconsistent results and updated evidence appraisal^{[6 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Cerebrolysin has no FDA-approved US prescribing information. There is no FDA-reviewed US label establishing indications, contraindications, adverse reactions, drug interactions, pregnancy safety, or monitoring requirements^{[1 –3 ]}.

Non-US prescribing information

The manufacturer summary based on Austrian prescribing information lists contraindications including hypersensitivity, epilepsy, and severe renal impairment^{[1 ]}. These are non-US prescribing-information details and should be verified against local product information if discussing non-US use^{[1 ]}.

Tolerability vs. systematic-review caution

The 2009 dementia review described Cerebrolysin as generally well tolerated in clinical trials, with dizziness or vertigo the most frequently reported adverse event^{[4 ]}. Cochrane’s acute ischemic stroke review was more cautious and concluded that Cerebrolysin probably increases serious non-fatal adverse events^{[5 ]}.

Animal-derived complex mixture

Animal-derived complex mixtures raise quality and identity questions distinct from single synthetic peptides. Product source, manufacturing controls, batch consistency, viral/prion risk controls, and cold-chain integrity are all relevant, but this draft did not identify FDA-reviewed US manufacturing data.

Long-term safety data in US clinical practice are absent because Cerebrolysin is not FDA-approved or marketed in the United States^{[1 –3 ]}. Online sourcing or self-importation introduces additional risks related to authenticity, storage, labeling, and legal status.

Available through

Cerebrolysin is not currently available through FDA-compliant channels in the United States. It is not FDA-approved and the manufacturer states it is not approved for sale or distribution in the United States^{[1 ]}.

ProPeptideGuide does not link to or endorse imported Cerebrolysin sellers, online pharmacies, research-chemical vendors, or clinics advertising noncompliant US access.